Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Inclusion Criteria:

* Patients with non-Hodgkin's B-cell lymphoma (NHL) including follicular, large cell and Mantle cell lymphoma will be included.
* Patients in complete clinical remission and determined to have no evidence of active disease (NED).
* Ambulatory, medically stable persons; community dwelling; able to give informed consent and available for all study visits; able to understand and comply with planned study procedures; ECOG performance status less than or equal to 2.
* Medically stable subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease, or hypothyroidism, but their symptoms/signs are controlled with medical therapy.
* Patients with a non-metastatic secondary solid tumor or malignancies not currently (\< 3 months) being treated will be included.
* Patients greater than or equal to 18 years of age who have given informed consent and signed the IRB approved informed consent.

Exclusion Criteria:

* Patients with Hodgkin's disease, and T-cell lymphoma.
* Patients undergoing antineoplastic therapy.
* Patients who have received chemotherapy within the past 3 months.
* Individuals who were given rituximab (ibritumomab tiuxetan) in \< 6 months.
* Patients receiving systemic corticosteroids and/or high-dose inhaled steroids (\>800 mcg per day of beclomethasone dipropionate or equivalent).
* Splenectomized individuals will not be included.
* Known allergy to eggs or other components of vaccine (e.g., thimerosal).
* Acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses (including but not limited to the following: acute febrile illness, known chronic liver disease; significant renal disease; oxygen-dependent chronic lung disease, New York Heart Association Functional Class III or IV dyspnea; unstable or progressive neurologic disorder; insulin-dependent diabetes mellitus).
* Concomitant use of investigational vaccines and/or other medications within 4 weeks prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products prior to study completion.
* Previous exposure to parenteral immunoglobulins or other blood product within 6 months prior to enrollment into the study.
* Subject is enrolled in a conflicting clinical trial.
* Use of experimental vaccines or medications within one month of study entry.
* Any acute or chronic condition which in the opinion of the investigator would render vaccination unsafe or interfere with the evaluation of response.
* Patients with a known history or risk factors (IV drug abuse or casual sex within the past year) of Hepatitis B, Hepatitis C, or Human Immunodeficeincy Virus.